rheumatology
Rheumatoid arthritis

Ultra-low dose rituximab possible in RA


Ultra-low dose rituximab may be considered for patients with rheumatoid arthritis already responding well to standard doses of the biologic, research suggests. While a Dutch study was unable to demonstrate non-inferiority at six months after dosing, it found most patients maintained good disease control on the ultra low dose. The REDO study randomised 142 patients ...

Already a member?

Login to keep reading.


OR
© 2019 the limbic